Trautmann A, Boyer O, Hodson E, Bagga A, Gipson DS, Samuel S et al (2023) IPNA clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndrome. Pediatr Nephrol 38:877–919. https://doi.org/10.1007/s00467-022-05739-3

Article  PubMed  Google Scholar 

Basu B, Erdmann S, Sander A, Mahapatra TKS, Meis J, Schaefer F (2023) Long-term efficacy and safety of rituximab versus tacrolimus in children with steroid dependent nephrotic syndrome. Kidney Int Rep 8:1575–1584. https://doi.org/10.1016/j.ekir.2023.05.022

Article  PubMed  PubMed Central  Google Scholar 

Iijima K, Sako M, Nozu K, Mori R, Tuchida N, Kamei K et al (2014) Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 384:1273–1281. https://doi.org/10.1016/S0140-6736(14)60541-9

Article  CAS  PubMed  Google Scholar 

Ravani P, Rossi R, Bonanni A, Quinn RR, Sica F, Bodria M et al (2015) Rituximab in children with steroid-dependent nephrotic syndrome: a multicenter, open-label, noninferiority, randomized controlled trial. J Am Soc Nephrol 26:2259–2266. https://doi.org/10.1681/ASN.2014080799

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sellier-Leclerc A-L, Baudouin V, Kwon T, Macher M-A, Guérin V, Lapillonne H et al (2012) Rituximab in steroid-dependent idiopathic nephrotic syndrome in childhood- -follow-up after CD19 recovery. Nephrol Dial Transplant 27:1083–1089. https://doi.org/10.1093/ndt/gfr405

Article  CAS  PubMed  Google Scholar 

Boye J, Elter T, Engert A (2003) An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann Oncol 14:520–535. https://doi.org/10.1093/annonc/mdg175

Article  CAS  PubMed  Google Scholar 

Hogan J, Dossier C, Kwon T, Macher M-A, Maisin A, Couderc A et al (2019) Effect of different rituximab regimens on B cell depletion and time to relapse in children with steroid-dependent nephrotic syndrome. Pediatr Nephrol 34:253–259. https://doi.org/10.1007/s00467-018-4052-x

Article  PubMed  Google Scholar 

Chan E-H, Webb H, Yu E, Ghiggeri GM, Kemper MJ, Ma A-T et al (2020) Both the rituximab dose and maintenance immunosuppression in steroid-dependent/frequently-relapsing nephrotic syndrome have important effects on outcomes. Kidney Int 97:393–401. https://doi.org/10.1016/j.kint.2019.09.033

Article  CAS  PubMed  Google Scholar 

Lee YH, Bae S-C, Song GG (2011) The efficacy and safety of rituximab for the treatment of active rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials. Rheumatol Int 31:1493–1499. https://doi.org/10.1007/s00296-010-1526-y

Article  CAS  PubMed  Google Scholar 

Trivin C, Tran A, Moulin B, Choukroun G, Gatault P, Courivaud C et al (2017) Infectious complications of a rituximab-based immunosuppressive regimen in patients with glomerular disease. Clin Kidney J 10:461–469. https://doi.org/10.1093/ckj/sfw101

Article  PubMed  Google Scholar 

Parmentier C, Delbet J-D, Decramer S, Boyer O, Hogan J, Ulinski T (2020) Immunoglobulin serum levels in rituximab-treated patients with steroid-dependent nephrotic syndrome. Pediatr Nephrol 35:455–462. https://doi.org/10.1007/s00467-019-04398-1

Article  PubMed  Google Scholar 

Chan E-H, Yu ELM, Angeletti A, Arslan Z, Basu B, Boyer O et al (2022) Long-term efficacy and safety of repeated rituximab to maintain remission in idiopathic childhood nephrotic syndrome: an international study. J Am Soc Nephrol 33:1193–1207. https://doi.org/10.1681/ASN.2021111472

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gea-Banacloche JC (2010) Rituximab-associated infections. Semin Hematol 47:187–198. https://doi.org/10.1053/j.seminhematol.2010.01.002

Article  CAS  PubMed  Google Scholar 

Sellier-Leclerc A-L, Belli E, Guérin V, Dorfmüller P, Deschênes G (2013) Fulminant viral myocarditis after rituximab therapy in pediatric nephrotic syndrome. Pediatr Nephrol 28:1875–1879. https://doi.org/10.1007/s00467-013-2485-9

Article  PubMed  Google Scholar 

Sato M, Ito S, Ogura M, Kamei K, Miyairi I, Miyata I et al (2013) Atypical Pneumocystis jiroveci pneumonia with multiple nodular granulomas after rituximab for refractory nephrotic syndrome. Pediatr Nephrol 28:145–149. https://doi.org/10.1007/s00467-012-2286-6

Article  PubMed  Google Scholar 

Bertrand Q, Mignot S, Kwon T, Couderc A, Maisin A, Cambier A et al (2022) Anti-rituximab antibodies in pediatric steroid-dependent nephrotic syndrome. Pediatr Nephrol 37:357–365. https://doi.org/10.1007/s00467-021-05069-w

Article  PubMed  Google Scholar 

Inoki Y, Nishi K, Sato M, Ogura M, Kamei K (2023) The association between hypogammaglobulinemia severity and infection risk in rituximab-treated patients with childhood-onset idiopathic nephrotic syndrome. Pediatr Nephrol 38:451–460. https://doi.org/10.1007/s00467-022-05652-9

Article  PubMed  Google Scholar 

Zurowska A, Drozynska-Duklas M, Topaloglu R, Bouts A, Boyer O, Shenoy M et al (2023) Rituximab-associated hypogammaglobulinemia in children with idiopathic nephrotic syndrome: results of an ESPN survey. Pediatr Nephrol 38:3035–3042. https://doi.org/10.1007/s00467-023-05913-1

Article  PubMed  PubMed Central  Google Scholar 

Inoki Y, Kamei K, Nishi K, Sato M, Ogura M, Ishiguro A (2022) Incidence and risk factors of rituximab-associated hypogammaglobulinemia in patients with complicated nephrotic syndrome. Pediatr Nephrol 37:1057–1066. https://doi.org/10.1007/s00467-021-05304-4

Article  PubMed  Google Scholar 

Delbe-Bertin L, Aoun B, Tudorache E, Lapillone H, Ulinski T (2013) Does rituximab induce hypogammaglobulinemia in patients with pediatric idiopathic nephrotic syndrome? Pediatr Nephrol 28:447–451. https://doi.org/10.1007/s00467-012-2361-z

Article  PubMed  Google Scholar 

Labrosse R, Barmettler S, Derfalvi B, Blincoe A, Cros G, Lacombe-Barrios J et al (2021) Rituximab-induced hypogammaglobulinemia and infection risk in pediatric patients. J Allergy Clin Immunol 148:523-532.e8. https://doi.org/10.1016/j.jaci.2021.03.041

Article  CAS  PubMed  Google Scholar 

Paul F, Cartron G (2019) Infusion-related reactions to rituximab: frequency, mechanisms and predictors. Expert Rev Clin Immunol 15:383–389. https://doi.org/10.1080/1744666X.2019.1562905

Article  CAS  PubMed  Google Scholar 

Dossier C, Bonneric S, Baudouin V, Kwon T, Prim B, Cambier A et al (2023) Obinutuzumab in frequently relapsing and steroid-dependent nephrotic syndrome in children. Clin J Am Soc Nephrol 18:1555–1562. https://doi.org/10.2215/CJN.0000000000000288

Article  PubMed  PubMed Central  Google Scholar 

Hengel FE, Dehde S, Lassé M, Zahner G, Seifert L, Schnarre A et al (2024) Autoantibodies targeting nephrin in podocytopathies. N Engl J Med 391:422–433. https://doi.org/10.1056/NEJMoa2314471

Article  CAS  PubMed  Google Scholar 

Watts AJB, Keller KH, Lerner G, Rosales I, Collins AB, Sekulic M et al (2022) Discovery of autoantibodies targeting nephrin in minimal change disease supports a novel autoimmune etiology. J Am Soc Nephrol 33:238–252. https://doi.org/10.1681/ASN.2021060794

Article  CAS  PubMed  Google Scholar 

Dossier C, Delbet J-D, Boyer O, Daoud P, Mesples B, Pellegrino B et al (2019) Five-year outcome of children with idiopathic nephrotic syndrome: the NEPHROVIR population-based cohort study. Pediatr Nephrol 34:671–678. https://doi.org/10.1007/s00467-018-4149-2

Article  PubMed  Google Scholar 

Fakhouri F, Bocquet N, Taupin P, Presne C, Gagnadoux M-F, Landais P et al (2003) Steroid-sensitive nephrotic syndrome: from childhood to adulthood. Am J Kidney Dis 41:550–557. https://doi.org/10.1053/ajkd.2003.50116

Article  PubMed  Google Scholar 

Kabuki N, Okugawa T, Hayakawa H, Tomizawa S, Kasahara T, Uchiyama M (1998) Influence of age at onset on the outcome of steroid-sensitive nephrotic syndrome. Pediatr Nephrol 12:467–470. https://doi.org/10.1007/s004670050489

Article  CAS  PubMed